ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 2536 • ACR Convergence 2024

    Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium

    Kevin Bu1, Rebecca Blank2, Adam Cantor1, Alba Boix-Amoros3, Jose Scher4 and Jose Clemente1, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), 1Icahn School of Medicine at Mount Sinai, New York, NY, 2NYU, New York, NY, 3Icahn School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY

    Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
  • Abstract Number: 0109 • ACR Convergence 2024

    Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Rohan Willis1, Anne Tebo2, Leslie Skeith3, Nina Kello4, H Michael Belmont5, Paul Fortin6, Guilherme Ramires de Jesús7, David Branch8, Michelle Petri9, Jason Knight10, Reyhan Kose Cobanoglu11, Maria Laura Bertolaccini12, Hannah Cohen13, Robert Roubey14, Doruk Erkan15 and Danieli Andrade16, and on behalf of APS ACTION, 1University of Texas Medical Branch, Galveston, TX, 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 3University of Calgary, Calgary, ON, Canada, 4Northwell Health, Brooklyn, NY, 5NYU School of Medicine, New York, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 8University of Utah and Intermountain Healthcare, Salt Lake City, UT, 9Johns Hopkins University School of Medicine, Timonium, MD, 10University of Michigan, Ann Arbor, MI, 11Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 12King's College London, London, United Kingdom, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 15Hospital for Special Surgery, New York, NY, 16University of São Paulo, São Paulo, SP, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
  • Abstract Number: 0463 • ACR Convergence 2024

    Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis

    Jose Antonio Davila Jimenez1, Dionicio Galarza-Delgado2, Iris Jazmín Colunga Pedraza3, jose Ramon Azpiri-Lopez4, Rosa Icela Arvizu-Rivera3, Jesus Cardenas-de la Garza5, Aleydis Gonzalez Melendez3, Andrea Guajardo Aldaco3, Maria F. Elizondo-Benitez6, Rebeca L. Polina-Lugo3 and Diego Salcedo-Almanza7, 1Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 2UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 7Division of Radiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk compared to the general population. All stages of the atherogenic process appear to…
  • Abstract Number: 0575 • ACR Convergence 2024

    Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA

    Kurt de Vlam1, Pieter Ruytinx2, Elien luyten2, Anouk Agten2, Frank Vandenabeele2 and Veerle somers2, 1Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, 2Universiteit Hasselt, Hasselt, Belgium

    Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
  • Abstract Number: 0696 • ACR Convergence 2024

    MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers

    Stefano Di Donato1, Rebecca Ross2, Yassir El-Sherbiny3, Riccardo Bixio4, Marco Minerba5, Christopher Wasson6, Jun Li7, Jochen SCHMITZ8, Sudha Visvanathan9 and Francesco Del Galdo6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Medicine and Health, University of Leeds, Leeds, United Kingdom, 3Nottingham Trent University, Nottingham, United Kingdom, 4University of Verona, Verona, Verona, Italy, 51. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, 6University of Leeds, Leeds, United Kingdom, 7Boehringer Ingelheim, Danbury, CT, 8Boehringer-Ingelheim, Ridgefield, CT, 9Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT

    Background/Purpose: Circulating endothelial cells (CEC) and their precursors have been shown to correlate to the severity of vascular manifestations in Systemic sclerosis1, such as Digital…
  • Abstract Number: 0849 • ACR Convergence 2024

    Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study

    Adrián Martín-Gutiérrez1, Javier Loricera2, Carmen Secada Gómez3, Iñigo Hernández-Rodríguez4, Susana Romero Yuste5, Eugenio De Miguel6, Eva Galindez-Agirregoikoa7, ivan Ferraz-Amaro8, Julio Sánchez-Martín9, Patricia Moya Albarado10, Cristina Campos Fernández11, Fernando Lopez-Gutierrez12, Santos Castañeda13 and Ricardo Blanco-Alonso14, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 5Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 6Hospital Universitario La Paz, Madrid, Spain, 7BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 8Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Hospital de San Pau, Barcelona, Spain, 11Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, 12Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 13Hospital Universitario de la Princesa, Madrid, Spain, 14Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Giant Cell Arteritis (GCA) was initially described involving mainly the extracranial branches of the carotid arteries. However, GCA also may involve the aorta (GCA-aortitis)…
  • Abstract Number: 1090 • ACR Convergence 2024

    Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy

    Naomi Schlesinger1, Katie Obermeyer2, Lissa Padnick-Silver2, Brian LaMoreaux3 and Peter Lipsky4, 1University of Utah, Salt Lake City, UT, 2Amgen, Inc., Thousand Oaks, CA, 3Amgen, Inc., Deerfield, IL, 4AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…
  • Abstract Number: 1317 • ACR Convergence 2024

    Serum (1-3)-β-D-Glucan Levels in Juvenile Idiopathic Arthritis

    Yasmine LAMROUS, Camille LEGLISE, Audrey VANRENTERGHEM, Taieb CHOUAKI and Djamal-Dine DJEDDI, CHU AMIENS PICARDIE, AMIENS, France

    Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses the most common chronic rheumatologic manifestations in children. It results from the interplay of genetic, environmental, and infectious factors.…
  • Abstract Number: 1570 • ACR Convergence 2024

    Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung

    Sunhwa Kim1, Yingtao Bi2, Vishal Kakkar3, Rebecca Ross4 and Francesco Del Galdo3, 1AbbVie, South San Francisco, CA, 2Abbvie, Worcester, MA, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease with variable clinical presentations and progression rates. Accurate patient stratification is crucial for optimizing treatment strategies.…
  • Abstract Number: 1808 • ACR Convergence 2024

    Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients

    Paula Losada Vanegas1, Juan Antonio Villatoro-García2, Daniel Rodriguez3, Juan Camilo Diaz3, Ricardo Pineda4, Pedro Carmona-Saez5, Mauricio Rojas6 and Gloria Vasquez7, 1Universidad de Antioquia, Medellin, Antioquia, Colombia, 2GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Andalucia, Spain, 3ARTMEDICA, Medellín, Antioquia, Colombia, 4ARTMEDICA, Medellin, Antioquia, Colombia, 5GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Asturias, Spain, 6Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina. Universidad de Antioquia, Medellin, Antioquia, Colombia, 7Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina.Universidad de Antioquia, Medellin, Colombia

    Background/Purpose: Monocytes play an important role in organ damage, such as in Lupus Nephritis (LN). Although monocytes are typically considered inflammatory cells, evidence shows they…
  • Abstract Number: 2102 • ACR Convergence 2024

    Unraveling Knee Osteoarthritis Subtypes: Differential Effect of Oral Salmon Calcitonin Treatment

    Monica Hannani1, Peder Frederiksen2, Morten Karsdal2, Asger Reinstrup Bihlet3, Jaume Bacardit4, Anne-Christine Bay-Jensen2 and Christian Thudium2, 1Nordic Bioscience & University of Copenhagen, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3NBCD A/S, Soeborg, Denmark, 4School of Computing, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Osteoarthritis (OA) patients are to this day left without effective treatment options. Despite different etiologies, trials designs do not account for the substantial heterogeneity…
  • Abstract Number: 2357 • ACR Convergence 2024

    Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies

    Joseph Merola1, Alexis Ogdie2, Arthur Kavanaugh3, Evan Leibowitz4, Emmanouil Rampakakis5, Ryan Funk6, Francois Nantel7, Frederic Lavie8, Katelyn Rowland9 and Enrique R. Soriano10, 1UT Southwestern Medical Center, Newton, MA, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3University of California San Diego, La Jolla, CA, 4Janssen Scientific Affairs, LLC, Fair Lawn, NJ, 5McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 6Johnson & Johnson Innovative Medicine, Long Grove, IL, 7Nantel MedSci Consult, Montreal, QC, Canada, 8Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 9Janssen Pharmaceuticals, Horsham, PA, 10Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Psoriatic disease (PsD) is associated with an increased risk of cardiovascular (CV) disease. Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of systemic inflammation; NLR ≥2.5…
  • Abstract Number: 2561 • ACR Convergence 2024

    Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

    Natalie McCormick1, Amit Joshi2, Robert Terkeltaub3, Tony Merriman4, Matthew Nayor5, Chio Yokose6 and Hyon K. Choi7, 1Massachusetts General Hospital, Boston, MA, 2Channing Division of Network Medicine, Boston, MA, 3Retired, San Diego, CA, 4University of Alabama at Birmingham, Homewood, AL, 5Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 6Massachusetts General Hospital, Waltham, MA, 7Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout.  A previous cross-sectional study of pre-existing gout (n=330…
  • Abstract Number: 0229 • ACR Convergence 2024

    An Early Inflammatory Cardiac Phenotype and Association with Future Coronary Plaque Burden in Rheumatoid Arthritis

    Brittany Weber1, Feng Liu2, Mary Jeffway2, Dana Weisenfeld2, Gregory McDermott3, Elena Massarotti2, Jonathan Coblyn2, Michael Weinblatt4, Marcelo Di Carli2, Damini Dey5 and Katherine Liao2, 1Brigham and Women's Hospital, DEDHAM, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Brookline, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Cedars-Sinai Medical Center, Los Angeles

    Background/Purpose: Patients with RA are at increased risk of cardiovascular disease (CVD) compared to the general population.  In a prior study of RA patients with…
  • Abstract Number: 0464 • ACR Convergence 2024

    Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population

    Amir Razmjou1, Rong Guo2, David Elashoff3, Kevin Deane4, Jill Norris5, Marie Feser6, Jennifer Wang1, Ani Shahbazian2 and christina Charles-Schoeman7, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Department of Medicine Statistics Core, Los Angeles, 4University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 5Colorado School of Public Health, Denver, CO, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 7UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Rheumatoid arthritis (RA) has a well described pre-clinical state, with a continuum of genetic and environmental risk factors leading to the development of systemic…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology